Morphosys Ag (MOR) has released an update.
MorphoSys AG has announced significant changes to its management board following a takeover offer from Novartis BidCo AG, with Arkadius Pichota and Lukas Gilgen taking over as CEO and CFO, respectively. This leadership shift occurs after the resignation of multiple supervisory board members and the appointment of new ones by the Munich Local Court. The company continues its mission to develop innovative cancer treatments and is headquartered in Germany with operations in Boston, Massachusetts.
For further insights into MOR stock, check out TipRanks’ Stock Analysis page.
